Could a common heart pill help those with artificial valves?

NCT ID NCT07192341

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether the drug sacubitril/valsartan (Entresto) can improve heart function in people who have a prosthetic (artificial) heart valve and heart failure with reduced pumping ability. About 220 adults will either get the drug plus standard care, or standard care alone. The main goal is to see if their heart failure symptoms improve by at least one grade on a standard scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sacubitril/valsartan (Entresto)
What this could lead to
If it works, this could offer a new treatment option for people with prosthetic heart valves who also have heart failure, potentially improving their heart function and daily life.
What could go wrong
This is a relatively small, early-stage trial (220 participants) and not yet a large Phase 3 study. The drug may not work better than standard therapy, and side effects like low blood pressure or kidney issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kafrelsheikh University

    RECRUITING

    Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.